Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
월요일, 8월 31

Teva Pharmaceutical Industries Ltd

TEVANYSE
Trade with Public
Trade with Public
$36.05
-0.39-1.07%
가까이에: Aug 31, 5:00 PM EST
$36.90
0.852.36%
시간외: 4:32 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Teva Pharmaceutical Indus Analyst Price Targets

Wall Street analyst price targets and consensus rating for Teva Pharmaceutical Indus (TEVA).

Price Target Range — 13 Quarters

Analyst Consensus — 9 Analysts

9Buy
Consensus RatingBuy# Analysts9Avg. Consensus PT$36Upside to Avg. PT-2.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 12, 2026BarclaysGlen SantangeloPT RaiseOverweight$40→$42
Jul 28, 2026Piper SandlerDavid AmsellemPT RaiseOverweight$42→$44
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42

Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $40 to $42.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $44

Piper Sandler analyst David Amsellem maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $42 to $44.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $40

Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $38 to $40.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $40

JP Morgan analyst Chris Schott maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $35 to $40.
Benzinga Newsdesk

PRO
UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $42

UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $36 to $42.
Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42

Piper Sandler analyst David Amsellem reiterates Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $41 to $42.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved